Fresenius Medical Care sets November 3 results date for Fresenius Medical Care stock

Published on 10/27/2026 at 16:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue hit EUR 4.86 billion in second-quarter 2026. Fresenius Medical Care stock costs EUR 40.61 on October 27, 2026, up 0.37 percent versus Xetra close.

Reporting date and earnings

Fresenius Medical Care will publish third-quarter 2026 figures on November 3, 2026.
Second-quarter 2026 revenue reached EUR 4.86 billion, up 1.46 percent from EUR 4.79 billion.
Fresenius Medical Care stock costs EUR 40.61 at Lang & Schwarz on October 27, 2026 at 4:01 p.m. CET, 0.37 percent above the Xetra close of October 26, 2026.
Seventeen analysts had an average target of EUR 41.86, 3.08 percent above the price.

FMC, DE0005785802, Illustration mit AI erstellt.

Fresenius Medical Care (ISIN DE0005785802) will publish its third-quarter 2026 figures on November 3, 2026, according to Fresenius Medical Care. The date gives investors a fixed point after a quarter in which the company reported mixed second-quarter trends. Fresenius Medical Care was trading at EUR 40.61 at Lang & Schwarz on October 27, 2026 at 4:01 p.m. CET, plus 0.37 percent versus the Xetra close of October 26, 2026 at EUR 40.46.

Revenue grew in the second quarter

For the second quarter of 2026, revenue reached EUR 4.86 billion, compared with EUR 4.79 billion in the second quarter of 2025. That represents growth of 1.46 percent. Net income was EUR 218.00 million, down 3.22 percent from EUR 225.27 million a year earlier, according to Markets Insider. The figures cover the quarter ended June 30, 2026 and put the November report under a clear earnings test.

Price remains below the analyst average

The latest consensus cited by MarketScreener covered 17 analysts and showed an average target of EUR 41.86. That target lies 3.08 percent above the Lang & Schwarz price. The same overview listed a Hold consensus, while J.P. Morgan maintained a Sell rating and a EUR 32.30 target on October 23, 2026.

November dates define the next test

The company scheduled publication of its third-quarter figures for November 3, 2026. Its investor calendar also lists the quarterly financial report for November 6, 2026, followed by an investor roadshow in London on November 4 and in Frankfurt on November 5. These dates separate the headline results release from the fuller report and management meetings.

Fresenius Medical Care and its peers

Fresenius Medical Care operates dialysis clinics and supplies equipment and related services for kidney care. DaVita traded at USD 181.13 on October 27, 2026, down 1.58 percent from its prior close, while Baxter International traded at USD 25.06, down 0.91 percent. Those peer prices provide context, but the November 3 report remains the next company-specific event.

Stock stays near EUR 41

The scheduled report and the revenue comparison give investors two measurable reference points for the next update. Revenue growth was positive in the second quarter, while net income moved lower, leaving the earnings mix as important as the headline sales figure. Fresenius Medical Care was trading at EUR 40.61 at Lang & Schwarz on October 27, 2026 at 4:01 p.m. CET, plus 0.37 percent versus the Xetra close of October 26, 2026 at EUR 40.46. The further course of trading is shown by the continuously updated real-time quote of Fresenius Medical Care stock.